09 November 2023
09 November 2023
At the BIO-Europe conference, early-stage investors highlighted the importance of translational funding in a risk-averse climate.
The company’s cash reduction measures are expected to extend its cash runway into 2026.
The company plans to utilise the proceeds to develop its lead programme and other programmes in CNS and neuromuscular ailments.
At the BIO-Europe Conference, an expert panel discussed challenges with the upcoming EU harmonisation of HTAs.
Mounjaro is indicated for obese and overweight adults, along with a lower-calorie diet and exercise.
OMERS has gained financial upsides for Ultomiris and Monjuvi sales from July 2023, with Xencor retaining a portion of sales-based milestones.
Alfasigma will also gain access to Intercept’s severe alcohol-associated hepatitis (sAH) drug INT-787 currently in a Phase IIa study.
The deal makes Danish Wiik Pharma the sole distributor of Telix’s prostate cancer imaging agent Illuccix across four European territories.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
